Etta Pisano, MD, FACR, principal investigator of the Tomosynthesis Mammographic Imaging Screening Trial contributed this post.
I wanted to thank the breast imaging community for the tremendous response that the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has recently received.
The number of patients enrolled in TMIST has doubled in recent months. New facilities are coming on board every week. Sessions at the 2019 Society of Breast Imaging (SBI)/American College of Radiology (ACR) Breast Imaging Symposium and other recent meetings have drawn tremendous interest.
On June 20, the National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) will present “TMIST: A Three-Dimensional Approach to Early Breast Cancer Detection,” the next installment in the “Women’s Health Seminar Series.”*
Interest continues to grow as more radiologists find out about the trial, what we are trying to do and how taking part in TMIST can strengthen your practice, expand screening access to the uninsured and shape future breast cancer screening.
Nearly 70 sites throughout North America are already taking part. We would like to add many more in the coming months.
I invite you to visit acr.org/TMIST to get more information on how your practice can take part in the largest randomized controlled breast cancer screening trial in decades.
You can also email TMIST@acr.org with any questions you may have about TMIST.
We hope to hear from you soon.
Please share your thoughts in the comments section below and join the discussion on Engage (login required).
*Continuing Medical Education (CME) credits are available for this NIH seminar.
